Trial reports myelin repair success
Repairing the damage to nerves caused by MS is possible, according to new research.
A study of the cancer drug bexarotene in Cambridge and Edinburgh showed that it led to the regrowth of myelin in people with relapsing remitting MS. However, the dose needed to produce this effect also led to serious side effects including thyroid disease and potentially damaging levels of blood fats. The results were presented at the MS Virtual conference.
Although the fact that it is possible to encourage the regrowth if myelin in humans is a breakthrough and will leads to further research, the side effects mean that bexarotene will not become a treatment for MS.
The Cambridge team are planning another remyelination study using metformin (a diabetes drug) in combination with clemastine (a treatment for hay fever and allergies)
Find out more
Ozanimod (Zeposia) approved for relapsing remitting MS in Scotland
8 Feb 2021 - 00:00
The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.
Exercise is good for your brain
3 Feb 2021 - 00:00
There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.
Covid-19 vaccines and MS: Part two
29 Jan 2021 - 00:00
Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.
Receiving an MS diagnosis during my gender transition
22 Feb 2021 - 00:00
Chris shares his experience of being diagnosed with MS at the same time as starting hormone treatment and a surgical gender transition.
David's Diary- Should we all be saying yes to the Covid 19 vaccine?
18 Feb 2021 - 00:00
For the last few weeks our Enquiry Service at the MS Trust has been busy with questions about the vaccination. In his latest blog piece for the MS Trust, CEO David Martin asks the question, 'Should we all be saying yes to the Covid 19 vaccine?'
Monkey sox are back!
17 Feb 2021 - 00:00
...but this time they've gone casual! We are very excited to have partnered once again with Monkey Sox to bring you an exclusive MS Trust design.
Sign up to our emails
Get the latest news and research sent straight to your inbox. Find out first about the latest developments in MS treatments, plus updates on the work of the MS Trust.
Share
